期刊
EUROPEAN HEART JOURNAL
卷 33, 期 13, 页码 1615-U53出版社
OXFORD UNIV PRESS
DOI: 10.1093/eurheartj/ehr348
关键词
HDL; CETP inhibition; Endothelin; Endothelial dysfunction; Nitric oxide
资金
- Educational Grant through the Strategic Alliance of the Foundation of Cardiovascular Research
- University of Zurich, Switzerland
- Pfizer Inc., New York, USA
- Swiss National Research Foundation [310030-118353]
A marked increase in HDL notwithstanding, the cholesterol ester transfer protein (CETP) inhibitor torcetrapib was associated with an increase in all-cause mortality in the ILLUMINATE trial. As underlying mechanisms remain elusive, the present study was designed to delineate potential off-target effects of torcetrapib. Spontaneously hypertensive rats (SHRs) and WistarKyoto (WKY) rats were treated with torcetrapib (100 mg/kg/day; SHR-T and WKY-T) or placebo (SHR-P and WKY-P) for 3 weeks. Blood pressure transiently increased during the first 3 days of torcetrapib administration in SHRs and returned to baseline thereafter despite continued drug administration. Acetylcholine-induced endothelium-dependent relaxations of aortic rings were markedly impaired, and endothelial nitric oxide synthase (eNOS) mRNA and protein were down-regulated after 3 weeks of torcetrapib treatment in SHR (P 0.0001, 0.01, and 0.05, resp. vs. SHR-P). Torcetrapib reduced NO release in cultured aortic endothelial cells (P 0.01 vs. vehicle-treated cells) and increased generation of reactive oxygen species in aortas of SHR-T (P 0.05, vs. SHR-P). Vascular reactivity to endothelin-1 (ET-1) and aortic ET-1 tissue content were increased in SHR-T (P 0.05 vs. SHR-P). Importantly, the ET-1 receptor A/B (ETA/B) antagonist bosentan normalized endothelial function in SHR-T (P 0.05). Torcetrapib induces a sustained impairment of endothelial function, decreases eNOS mRNA, protein as well as NO release, stimulates vascular ROS and ET production, an effect that is prevented by chronic ETA/B-receptor blockade. These unexpected off-target effects of torcetrapib need to be ruled out in the clinical development of novel CETP inhibitors, particularly before a large patient population at increased cardiovascular risk is exposed to these compounds.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据